Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

Table 2

Endpoints identified in health technology assessment reports.

Category^a	Endpoint reported (% of category)
	Included in >1 cancer type	Malignant melanoma only	NSCLC only	RCC only
Clinical response ()	Complete response (11%); Duration of response (13%); Objective response rate (13%); Overall response rate (12%); Partial response (10%); Objective tumor response (8%); Disease control rate (4%); Stable disease (4%); Time to response (3%); Response rates (1%)	Disease progression (1%); Near complete response (1%)	Tumor response (12%); Best tumor response (1%); Physical functioning (1%); Symptomatic improvement (1%); Time to tumor progression (1%); Time to worsening of patient reported outcomes (1%); Tolerance (1%)
Disease progression ()	Progression-free survival (72%); Time to progression/progressive disease (15%)		Time to treatment failure (8%); Time to worsening of symptoms (3%)	Time to first event (2%)
Survival ()	Median OS (83%); 1-year survival (13%); 2-year survival (5%)
QoL ()	QoL (68%); Health-related QoL (20%)		Disease-specific questionnaire (4%); Lung cancer symptom scale (4%)	Patient reported outcomes (4%)

HTA reports may include more than one endpoint category.